These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16740653)

  • 1. Mullerian inhibiting substance regulates androgen-induced gene expression and growth in prostate cancer cells through a nuclear factor-kappaB-dependent Smad-independent mechanism.
    Tran TT; Segev DL; Gupta V; Kawakubo H; Yeo G; Donahoe PK; Maheswaran S
    Mol Endocrinol; 2006 Oct; 20(10):2382-91. PubMed ID: 16740653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mullerian-inhibiting substance induces Gro-beta expression in breast cancer cells through a nuclear factor-kappaB-dependent and Smad1-dependent mechanism.
    Gupta V; Yeo G; Kawakubo H; Rangnekar V; Ramaswamy P; Hayashida T; MacLaughlin DT; Donahoe PK; Maheswaran S
    Cancer Res; 2007 Mar; 67(6):2747-56. PubMed ID: 17363596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mullerian-inhibiting substance regulates NF-kappa B signaling in the prostate in vitro and in vivo.
    Segev DL; Hoshiya Y; Hoshiya M; Tran TT; Carey JL; Stephen AE; MacLaughlin DT; Donahoe PK; Maheswaran S
    Proc Natl Acad Sci U S A; 2002 Jan; 99(1):239-44. PubMed ID: 11773638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Müllerian inhibiting substance signaling uses a bone morphogenetic protein (BMP)-like pathway mediated by ALK2 and induces SMAD6 expression.
    Clarke TR; Hoshiya Y; Yi SE; Liu X; Lyons KM; Donahoe PK
    Mol Endocrinol; 2001 Jun; 15(6):946-59. PubMed ID: 11376113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutually antagonistic effects of androgen and activin in the regulation of prostate cancer cell growth.
    Carey JL; Sasur LM; Kawakubo H; Gupta V; Christian B; Bailey PM; Maheswaran S
    Mol Endocrinol; 2004 Mar; 18(3):696-707. PubMed ID: 14684851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mullerian Inhibiting Substance induces NFkB signaling in breast and prostate cancer cells.
    Hoshiya Y; Gupta V; Segev DL; Hoshiya M; Carey JL; Sasur LM; Tran TT; Ha TU; Maheswaran S
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):43-9. PubMed ID: 14656475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regulation of gonadotropin gene expression by Mullerian inhibiting substance.
    Bédécarrats GY; O'Neill FH; Norwitz ER; Kaiser UB; Teixeira J
    Proc Natl Acad Sci U S A; 2003 Aug; 100(16):9348-53. PubMed ID: 12878721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Müllerian-inhibiting substance regulates androgen synthesis at the transcriptional level.
    Teixeira J; Fynn-Thompson E; Payne AH; Donahoe PK
    Endocrinology; 1999 Oct; 140(10):4732-8. PubMed ID: 10499532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Müllerian inhibiting substance regulates its receptor/SMAD signaling and causes mesenchymal transition of the coelomic epithelial cells early in Müllerian duct regression.
    Zhan Y; Fujino A; MacLaughlin DT; Manganaro TF; Szotek PP; Arango NA; Teixeira J; Donahoe PK
    Development; 2006 Jun; 133(12):2359-69. PubMed ID: 16687449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interruption of nuclear factor kappaB signaling by the androgen receptor facilitates 12-O-tetradecanoylphorbolacetate-induced apoptosis in androgen-sensitive prostate cancer LNCaP cells.
    Altuwaijri S; Lin HK; Chuang KH; Lin WJ; Yeh S; Hanchett LA; Rahman MM; Kang HY; Tsai MY; Zhang Y; Yang L; Chang C
    Cancer Res; 2003 Nov; 63(21):7106-12. PubMed ID: 14612503
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y; Chatterjee SJ; Brands FH; Shi SR; Pootrakul L; Taylor CR; Datar R; Cote RJ
    BJU Int; 2006 Jan; 97(1):170-8. PubMed ID: 16336351
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced purification and production of Müllerian inhibiting substance for therapeutic applications.
    Donahoe PK; Clarke T; Teixeira J; Maheswaran S; MacLaughlin DT
    Mol Cell Endocrinol; 2003 Dec; 211(1-2):37-42. PubMed ID: 14656474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.
    Barbie TU; Barbie DA; MacLaughlin DT; Maheswaran S; Donahoe PK
    Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15601-6. PubMed ID: 14671316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
    Zerbini LF; Wang Y; Cho JY; Libermann TA
    Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NF-kappaB2/p52 enhances androgen-independent growth of human LNCaP cells via protection from apoptotic cell death and cell cycle arrest induced by androgen-deprivation.
    Nadiminty N; Chun JY; Lou W; Lin X; Gao AC
    Prostate; 2008 Dec; 68(16):1725-33. PubMed ID: 18781579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pubertal and adult Leydig cell function in Mullerian inhibiting substance-deficient mice.
    Wu X; Arumugam R; Baker SP; Lee MM
    Endocrinology; 2005 Feb; 146(2):589-95. PubMed ID: 15514087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone morphogenetic protein-2 induces hypophosphorylation of Rb protein and repression of E2F in androgen-treated LNCaP human prostate cancer cells.
    Tomari K; Kumagai T; Shimizu T; Takeda K
    Int J Mol Med; 2005 Feb; 15(2):253-8. PubMed ID: 15647840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell cycle regulator cdk2ap1 inhibits prostate cancer cell growth and modifies androgen-responsive pathway function.
    Zolochevska O; Figueiredo ML
    Prostate; 2009 Oct; 69(14):1586-97. PubMed ID: 19585490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFkappa B-mediated pathway.
    Segev DL; Ha TU; Tran TT; Kenneally M; Harkin P; Jung M; MacLaughlin DT; Donahoe PK; Maheswaran S
    J Biol Chem; 2000 Sep; 275(37):28371-9. PubMed ID: 10874041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Id-1 expression induces androgen-independent prostate cancer cell growth through activation of epidermal growth factor receptor (EGF-R).
    Ling MT; Wang X; Lee DT; Tam PC; Tsao SW; Wong YC
    Carcinogenesis; 2004 Apr; 25(4):517-25. PubMed ID: 14688027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.